Exiqon Launches LNA™ microRNA Mimics with No Off-Target Effect
Exiqon A/S has announced the launch of highly potent miRCURY LNA™ microRNA Mimics for functional analysis. The new miRCURY LNA™ microRNA Mimics enable sub-nanomolar potency and allow scientists to conduct high quality dose-response experiments for instance by resembling disease situations.
The highly potent miRCURY LNA™ microRNA Mimics serve to simulate the natural functions of endogenous microRNAs allowing scientists to investigate the biological function of a specific microRNA.
Exiqon has developed advanced computer models to optimize the use of its proprietary LNA™ technology and ensure that only the guide-strand is active as the passenger strand is segmented into two short LNA™ strands.
By applying a segmented passenger strand the passenger strand cannot be loaded into RISC which secures complete inactivity of the passenger strand thereby eliminating the main source for the well-known off-target effect of microRNA mimics.
In combination with Exiqon’s proprietary miRCURY LNA™ microRNA Inhibitors and miRCURY LNA™ microRNA Target site blockers the new miRCURY LNA™ microRNA Mimics constitute a comprehensive platform for the functional analysis of microRNAs in basic research and as disease biomarkers in novel diagnostics and therapeutic applications.
“This is truly an innovative product which addresses the many requests we have received from customers” says Henrik M. Pfundheller, SVP, Sales and Marketing, and continues “We are excited to now offer customers a comprehensive high-quality product range for the functional analysis of microRNA by adding mimics to our already very popular miRCURY LNA™ microRNA Inhibitors and Target Site Blockers”.